Endoplasmic Reticulum‐Targeting Iridium(III) Nanosonosensitizer Amplifies Immunogenic Cell Death for Boosted Tumor Sono‐Immunotherapy DOI
Xiaoyu Xu, Meixu Chen, Shan Jiang

et al.

Advanced Functional Materials, Journal Year: 2024, Volume and Issue: 34(26)

Published: Feb. 27, 2024

Abstract Reactive oxygen species (ROS)‐induced endoplasmic reticulum (ER) stress in sonodynamic therapy (SDT) can elicit immunogenic cell death (ICD)‐initiated antitumor immunity for augmented sono‐immunotherapy. However, unsatisfactory activity and mediocre ER induction ability of sonosensitizers essentially restrict SDT efficacy ICD stimulation. Herein, a versatile ER‐targeting Iridium(III) nanosonosensitizer is developed as superior inducer boosted tumor An ingenious cholic acid (CA)‐functionalized sonosensitizer Ir‐CA well‐designed skillfully crosslinked with human serum albumin (HSA) to form HSA@Ir‐CA. With high stability, favorable tumor‐targeting ability, reduction‐responsiveness, HSA@Ir‐CA preferentially accumulates sites enhanced cellular uptake, followed by rapid disassembly responding intracellular reductive environment. The uncaged selectively accumulate precisely disrupt situ produced type I II ROS upon US irradiation high‐efficiency SDT. Moreover, the maximized eminently amplifies evoke robust systemic immunity, inhibiting growths primary/distant tumor, lung metastasis, recurrence. This combined immune checkpoint inhibitor (αPD‐L1) further achieves reinforced therapeutic outcome against immunologically “cold” tumor. study presents an effective paradigm optimize amplify ICD‐initiated responses

Language: Английский

Nanocatalysts for modulating antitumor immunity: fabrication, mechanisms and applications DOI
Xianbo Wu, Yuqing Li, Mei Wen

et al.

Chemical Society Reviews, Journal Year: 2024, Volume and Issue: 53(5), P. 2643 - 2692

Published: Jan. 1, 2024

This review discusses the structures and engineering strategies of nanocatalysts, highlighting their underlying mechanisms applications in cancer immunotherapy.

Language: Английский

Citations

40
Ultrasound-Based Micro-/Nanosystems for Biomedical Applications DOI
Hui Huang,

Yi Zheng,

Meiqi Chang

et al.

Chemical Reviews, Journal Year: 2024, Volume and Issue: 124(13), P. 8307 - 8472

Published: June 26, 2024

Due to the intrinsic non-invasive nature, cost-effectiveness, high safety, and real-time capabilities, besides diagnostic imaging, ultrasound as a typical mechanical wave has been extensively developed physical tool for versatile biomedical applications. Especially, prosperity of nanotechnology nanomedicine invigorates landscape ultrasound-based medicine. The unprecedented surge in research enthusiasm dedicated efforts have led mass multifunctional micro-/nanosystems being applied biomedicine, facilitating precise diagnosis, effective treatment, personalized theranostics. deployment applications is rooted profound understanding relationship among composition, structure, property, bioactivity, application, performance. In this comprehensive review, we elaborate on general principles regarding design, synthesis, functionalization, optimization abundant particular, recent advancements imaging are meticulously summarized. Furthermore, systematically elucidate state-of-the-art studies concerning progress therapeutic targeting various pathological abnormalities including cancer, bacterial infection, brain diseases, cardiovascular metabolic diseases. Finally, conclude provide an outlook field with in-depth discussion challenges faced future developments further extensive clinical translation application.

Language: Английский

Citations

37
De Novo Designed Ru(II) Metallacycle as a Microenvironment‐Adaptive Sonosensitizer and Sonocatalyst for Multidrug‐Resistant Biofilms Eradication DOI
Yuling Xu,

Yida Pang,

Lishi Luo

et al.

Angewandte Chemie International Edition, Journal Year: 2024, Volume and Issue: 63(15)

Published: Feb. 8, 2024

Abstract Albeit sonodynamic therapy (SDT) has achieved encouraging progress in microbial sterilization, the scarcity of guidelines for designing highly effective sonosensitizers and intricate biofilm microenvironment (BME), substantially hamper therapeutic efficacy against infections. To address bottlenecks, we innovatively design a Ru(II) metallacycle‐based sonosensitizer/sonocatalyst (named Ru‐A3‐TTD ) to enhance potency sonotherapy by employing molecular engineering strategies tailored BME. Our approach involves augmenting ’s production ultrasonic‐triggered reactive oxygen species (ROS), surpassing performance commercial sonosensitizers, through straightforward but potent π‐expansion approach. Within BME, synergistically amplifies sonotherapeutic via triple‐modulated approaches: (i) alleviation hypoxia, leading increased ROS generation, (ii) disruption antioxidant defense system, which shields from glutathione consumption, (iii) enhanced penetration, enabling deep sites. Notably, sono‐catalytically oxidizes NADPH, critical coenzyme involved defenses. Consequently, demonstrates superior eradication multidrug‐resistant Escherichia coli compared conventional clinical antibiotics, both vitro vivo. our knowledge, this study represents pioneering instance supramolecular sonosensitizer/sonocatalyst. It provides valuable insights into structure‐activity relationship paves promising pathway treatment

Language: Английский

Citations

32
A Distinctive Insight into Inorganic Sonosensitizers: Design Principles and Application Domains DOI
Wen Qin, Qiaoling Yang, Chunyan Zhu

et al.

Small, Journal Year: 2024, Volume and Issue: 20(25)

Published: Jan. 15, 2024

Abstract Sonodynamic therapy (SDT) as a promising non‐invasive anti‐tumor means features the preferable penetration depth, which nevertheless, usually can't work without sonosensitizers. Sonosensitizers produce reactive oxygen species (ROS) in presence of ultrasound to directly kill tumor cells, and concurrently activate immunity especially after integration with microenvironment (TME)‐engineered nanobiotechnologies combined therapy. Current sonosensitizers are classified into organic inorganic ones, current most reviews only cover highlighted their applications. However, there have few specific that focus on including design principles, regulation, etc. In this review, first according rationales rather than composition, action underlying chemistry highlighted. Afterward, what how TME is regulated based sonosensitizers‐based SDT nanoplatform an emphasis targets‐engineered elucidated. Additionally, applications non‐cancer diseases also outlined. Finally, setbacks challenges, proposed potential solutions future directions pointed out. This review provides comprehensive detailed horizon sonosensitizers, will arouse more attentions SDT.

Language: Английский

Citations

29
Endoplasmic Reticulum‐Targeting Iridium(III) Nanosonosensitizer Amplifies Immunogenic Cell Death for Boosted Tumor Sono‐Immunotherapy DOI
Xiaoyu Xu, Meixu Chen, Shan Jiang

et al.

Advanced Functional Materials, Journal Year: 2024, Volume and Issue: 34(26)

Published: Feb. 27, 2024

Abstract Reactive oxygen species (ROS)‐induced endoplasmic reticulum (ER) stress in sonodynamic therapy (SDT) can elicit immunogenic cell death (ICD)‐initiated antitumor immunity for augmented sono‐immunotherapy. However, unsatisfactory activity and mediocre ER induction ability of sonosensitizers essentially restrict SDT efficacy ICD stimulation. Herein, a versatile ER‐targeting Iridium(III) nanosonosensitizer is developed as superior inducer boosted tumor An ingenious cholic acid (CA)‐functionalized sonosensitizer Ir‐CA well‐designed skillfully crosslinked with human serum albumin (HSA) to form HSA@Ir‐CA. With high stability, favorable tumor‐targeting ability, reduction‐responsiveness, HSA@Ir‐CA preferentially accumulates sites enhanced cellular uptake, followed by rapid disassembly responding intracellular reductive environment. The uncaged selectively accumulate precisely disrupt situ produced type I II ROS upon US irradiation high‐efficiency SDT. Moreover, the maximized eminently amplifies evoke robust systemic immunity, inhibiting growths primary/distant tumor, lung metastasis, recurrence. This combined immune checkpoint inhibitor (αPD‐L1) further achieves reinforced therapeutic outcome against immunologically “cold” tumor. study presents an effective paradigm optimize amplify ICD‐initiated responses

Language: Английский

Citations

19